In this episode of “The Top Line,” we explore the next potential wave of mental health therapy: psychedelics.
Fierce Biotech's Max Bayer sits down with Scott Aaronson, M.D., a seasoned clinician and psychiatrist with over 30 years of experience in the field. They discuss how psychedelics might be used in the treatment of conditions such as depression, substance addiction, PTSD, anorexia and more. They also examine the obstacles developers face as they advance their studies.
To learn more about the topics in this episode:
- MDMA approval filing nears after drug hits again in phase 3, showing consistent PTSD improvements
- Early clinical data on psilocybin in anorexia point Compass to potential new opportunity
- Otsuka adopts new Mindset, dropping $59M to buy Canadian psychedelic biotech